English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Indonesia has declared a COVID-19 outbreaks because of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) in March 2020. COVID-19 has significantly increased morbidity and mortality worldwide. Some studies have shown good clinical outcomes with the use of combination of chloroquine or hydroxychloroquine and azithromycin. That drugs can prolong the QT interval and increase the risk of Torsade de Pointes (TdP). The risk is increasing in several conditions such as in critical patients, metabolic disorders, sepsis, multiorgan dysfunction and with drug-drug interactions. Cardiologists need to know how to manage this condition to reduce the risk of TdP. (Indonesian J Cardiol. 2020;41:108-111) Keyword: COVID-19, hydroxychloroquine, azithromycin, QT prolongation, TdP 1 Faculty of medicine, Universitas Muhammadiyah Prof. DR. Hamka, Tangerang 2 Division of arrhythmia and electrophysiology, Department of cardiology and vascular medicine of National Cardiovascular Center of Harapan Kita, Faculty of medicine of Universitas Indonesia. 3 Division of arrhythmia and electrophysiology, Department of cardiology and vascular medicine, Faculty of medicine of Universitas Padjadjaran. Correspondence: Sidhi Laksono, FK UHAMKA Jl. Raden Patah No.01, RT.002/ RW.006, Parung Serab, Kec. Ciledug, Kota Tangerang, Banten 13460. E-mail: sidhilaksono@uhamka.ac.id Review Article doi: 10.30701/ijc.1002 Introduction Indonesia is currently suffering through a pandemic outbreak of Coronavirus Disease 2019 (COVID-19) that caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is a newly recognized viral infectious disease that has spread rapidly throughout Wuhan, Hubei, China and several countries around the world.1 The rapid spread of this disease has significantly increased in morbidity and mortality worldwide. Studies have shown clinically improved outcome with the use of chloroquine or hydroxychloroquine in COVID-19 patients, even though still controversial.2,3 Combination of azithromycin and hydroxychloroquine or with chloroquine significantly reduced SARS-CoV-2 in swab samples.4 Those combinations are known to prolong the QT interval and will increase the incident of Torsades de Pointes (TdP). The risk of TdP increases in critical patients, Indonesian J Cardiol 2020:41:108-111

Managing QT prolongation in the Era of Coronavirus Disease 2019 (COVID-19)